Investor Presentaiton
Strategic Investment - Delivering commitment on breakthrough technology
Highlights of our journey
Recent Collaboration and Initiative
☐
Increasing stake to ~88%
LAURUS Bio
September 2023
IIT KANPUR
Indian Institute of Technology Kanpur
June 2023
Immuno ACT
May 2023
wwwwww
CHROLO
Integrated offering with capabilities across rh-
Protein, Bio-catalysis & precision fermentation
■ In-licensed few gene therapy assets and
funding support to advance clinical trials
Setting-up GLP lab for Vectors and Gene
Therapy products
■ Additional infusion; Increasing stake to ~34%.
GMP facility on going expansion
■ Phase II completed for CD-19 targeting B-
lymphoid malignancies on 60 patients. Product
approval received from CDSCO1 (12-Oct 2023)
Precision
Fermentation
Gene
Therapy
8
◉
Acquired 26.6% in CAR-T cell platform co
November 2021
■ Aim to bring novel technology to cancer patients
at a very affordable pricing
1
Central Drugs Standard Control Organization (CDSCO)
Laurus Q2 & H1 FY 2024 Investor Presentation | October 20, 2023
Cell Therapy
Retain Goal
to Invest up to 10%
of profits on disruptive
technologies
~370 Crore
Cumulative Investment in
last 3 years consistent with
our Goal
LAURUS Labs
Knowledge. Innovation. ExcellenceView entire presentation